Abiopharma

🔍 Hohl Benjamin (Executive)

Company: Enliven Therapeutics, Inc. (ELVN)

Report Date: 2025-08-27

Detailed Transactions and Holdings:

• Acquired 3,250 shares of Common Stock at $2.48 per share (Direct)
  Date: 2025-08-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 26,250.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,250 shares of Common Stock at $20.6273 per share (Direct)
  Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 23,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 3,250 shares of Stock Option (right to buy) at $2.48 per share (Derivative)
  Date: 2025-08-27 | Code: M | Expires: 2031-08-02 | equity_swap_involved: 0 | shares_owned_after: 108,306.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
• F2: This transaction was executed in multiple trades at prices ranging from $20.27 to $20.8689. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F3: All of the shares subject to this option are fully vested and exercisable as of the date hereof.